Omacor Potential To Increase LDL Cholesterol Limits Use To Severe Patients
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Omacor indication limited to severe hypertriglyceridemia because of increased LDL-cholesterol associated with the drug, FDA review documents indicate. Ross was unable to support cardioprotective benefit or reduction of risk of pancreatitis; omega-3 fatty acids, also marketed in U.S. as a dietary supplement, is approved for cardiovascular outcomes in other countries
You may also be interested in...
FDA Clears 31 New Molecular Entities In 2004, Up 10 From Previous Year
NME rebound in 2004? Final count is 31 versus 21 in 2003 – however, 2004 tally includes several atypical new molecular entities. Top 10 pharma companies hold small share of the total, with no companies clearing more than two NMEs during the year. Over 20% of the approvals came in the last two weeks of December
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product